Haemate P (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Haemate P is indicated for the treatment and prophylaxis of bleeding in individuals with specific clotting factor deficiencies.

• Replacement therapy for patients with hemophilia A (factor VIII deficiency).
• Management of acute bleeding episodes in von Willebrand disease.
• Surgical or invasive procedure support to prevent peri‑operative hemorrhage in eligible patients.
• Long‑term prophylactic regimens to reduce frequency of spontaneous bleeds.
• Use in combination with other hemostatic agents when clinically appropriate.

Adverse reactions reported with Haemate P are generally consistent with other plasma‑derived factor concentrates.

Common

• Headache or mild fever.
• Injection site erythema, swelling, or discomfort.
• Transient increase in liver enzymes.
• Nausea or mild abdominal discomfort.
• Fatigue or malaise.

Serious

• Development of inhibitors (antibodies) against factor VIII.
• Anaphylactic or severe allergic reactions.
• Thromboembolic events such as deep‑vein thrombosis.
• Transmission of infectious agents (viral or prion) despite screening.
• Severe hypotension or shock following infusion.
• Renal impairment or hemolysis.

When prescribing Haemate P, clinicians should consider several precautionary measures to ensure patient safety.

• Assess for a history of inhibitors to factor VIII before initiating therapy.
• Evaluate for known hypersensitivity to any component of the product.
• Monitor for signs of infection or viral transmission, especially in immunocompromised patients.
• Use the lowest effective dose and adjust based on clinical response and laboratory parameters.
• Avoid rapid infusion rates that may increase the risk of adverse reactions.
• Conduct regular screening for thrombotic complications during prolonged treatment.

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid

• Concomitant use of high‑dose pro‑coagulant agents (e.g., activated factor VII) without specialist guidance.
• Simultaneous administration of other plasma‑derived clotting factor concentrates unless clinically indicated.

Use with caution

• Antifibrinolytic agents such as tranexamic acid, which may increase clot stability.
• Immunosuppressive drugs that could alter inhibitor development risk.
• Vaccines administered shortly before or after infusion, to avoid overlapping immune activation.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may exacerbate bleeding tendencies.